Emily Goff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emily Goff has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexa Badalamenti
Cancer Genetics Program, Simmons Comprehensive Cancer Center University of Texas Southwestern Medical Center Dallas Texas USA
1 shared publication - Ang Gao
O’Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication - Ashley N. Wercholuk
Department of Surgery, University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication - Caitlin B. Mauer Hall
Division of Cancer Genetics, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication - Chul Ahn
Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas
1 shared publication - Deborah Farr
Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
1 shared publication
Latest Publications
- 30 June 2025
- Published by Springer Nature in Journal of Community Genetics
- Vol. 16 (6) , 737-746
Exploring the role of germline genetic testing in surgical decision making for early-stage invasive breast cancer: insights from a safety-net hospital
Current guidelines recommend contralateral prophylactic mastectomy (CPM) for women with unilateral breast cancer who have pathogenic/likely pathogenic variants (PV) in high-risk genes, but not for those with variants of uncertain significance (VUS). However, VUS results can cause significant psychosocial distress, which may influence surgical decision-making. In safety-net settings, concerns about insurance coverage and additional social determinants of health may further impact CPM decisions. This study examines surgical trends among patients with early-stage invasive breast cancer who underwent genetic testing before surgery at a safety-net hospital in Dallas, Texas between 2012–2022. We performed a retrospective chart review of 300 early-stage breast cancer patients referred for genetic counseling, analyzing demographics, tumor characteristics, genetic testing results, and treatment. Descriptive statistics and regression analyses were performed. The cohort included 116 patients without mutations (control), 111 with VUS, and 73 with PV. 86.30% of PV patients, 30.63% of VUS patients, and 18.10% of the control group underwent CPM. Multivariate analysis identified PV (OR 26.35, 95% CI: 10.97–63.29, p < 0.0001), VUS (OR 2.35, 95% CI: 1.16–4.77, p = 0.0175), and age at diagnosis (OR 0.963, 95% CI: 0.934–0.993, p = 0.0168) as independent predictors of CPM. These findings suggest that factors beyond established guidelines may influence surgical decision-making, particularly for patients in safety-net hospital settings, underscoring the need for thorough provider and patient counseling.
- 30 June 2025
- Published by Springer Nature in Journal of Community Genetics
- Vol. 16 (6) , 737-746
Exploring the role of germline genetic testing in surgical decision making for early-stage invasive breast cancer: insights from a safety-net hospital
Current guidelines recommend contralateral prophylactic mastectomy (CPM) for women with unilateral breast cancer who have pathogenic/likely pathogenic variants (PV) in high-risk genes, but not for those with variants of uncertain significance (VUS). However, VUS results can cause significant psychosocial distress, which may influence surgical decision-making. In safety-net settings, concerns about insurance coverage and additional social determinants of health may further impact CPM decisions. This study examines surgical trends among patients with early-stage invasive breast cancer who underwent genetic testing before surgery at a safety-net hospital in Dallas, Texas between 2012–2022. We performed a retrospective chart review of 300 early-stage breast cancer patients referred for genetic counseling, analyzing demographics, tumor characteristics, genetic testing results, and treatment. Descriptive statistics and regression analyses were performed. The cohort included 116 patients without mutations (control), 111 with VUS, and 73 with PV. 86.30% of PV patients, 30.63% of VUS patients, and 18.10% of the control group underwent CPM. Multivariate analysis identified PV (OR 26.35, 95% CI: 10.97–63.29, p < 0.0001), VUS (OR 2.35, 95% CI: 1.16–4.77, p = 0.0175), and age at diagnosis (OR 0.963, 95% CI: 0.934–0.993, p = 0.0168) as independent predictors of CPM. These findings suggest that factors beyond established guidelines may influence surgical decision-making, particularly for patients in safety-net hospital settings, underscoring the need for thorough provider and patient counseling.